Literature DB >> 21672484

Botulinum toxin A should not be first-line therapy for overactive bladder.

Lesley K Carr1.   

Abstract

Entities:  

Year:  2011        PMID： 21672484      PMCID： PMC3114032          DOI： 10.5489/cuaj.11044

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  14 in total

1.  Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications.

Authors:  Markus Naumann; Alastair Carruthers; Jean Carruthers; Sheena K Aurora; Ross Zafonte; Susan Abu-Shakra; Terry Boodhoo; Mary Ann Miller-Messana; George Demos; Lynn James; Frederick Beddingfield; Amanda VanDenburgh; Mary Ann Chapman; Mitchell F Brin
Journal:  Mov Disord       Date:  2010-10-15       Impact factor: 10.338

Review 2.  Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity.

Authors:  Christopher Dowson; Mohammad Shamim Khan; Prokar Dasgupta; Arun Sahai
Journal:  Nat Rev Urol       Date:  2010-12       Impact factor: 14.432

3.  Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.

Authors:  D M Schmid; P Sauermann; M Werner; B Schuessler; N Blick; M Muentener; R T Strebel; D Perucchini; D Scheiner; G Schaer; H John; A Reitz; D Hauri; B Schurch
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

4.  Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.

Authors:  Sender Herschorn; Jerzy Gajewski; Karen Ethans; Jacques Corcos; Kevin Carlson; Gregory Bailly; Robert Bard; Luc Valiquette; Richard Baverstock; Lesley Carr; Sidney Radomski
Journal:  J Urol       Date:  2011-04-16       Impact factor: 7.450

5.  Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial.

Authors:  Roger Dmochowski; Christopher Chapple; Victor W Nitti; Michael Chancellor; Karel Everaert; Catherine Thompson; Grace Daniell; Jihao Zhou; Cornelia Haag-Molkenteller
Journal:  J Urol       Date:  2010-10-16       Impact factor: 7.450

Review 6.  The patient with an overactive bladder--symptoms and quality-of-life issues.

Authors:  S Jackson
Journal:  Urology       Date:  1997-12       Impact factor: 2.649

Review 7.  Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review.

Authors:  Gilles Karsenty; Pierre Denys; Gérard Amarenco; Marianne De Seze; Xavier Gamé; François Haab; Jacques Kerdraon; Brigitte Perrouin-Verbe; Alain Ruffion; Christian Saussine; Jean-Marc Soler; Brigitte Schurch; Emmanuel Chartier-Kastler
Journal:  Eur Urol       Date:  2007-10-16       Impact factor: 20.096

8.  Refractory idiopathic urge urinary incontinence and botulinum A injection.

Authors:  Linda Brubaker; Holly E Richter; Anthony Visco; Sangeeta Mahajan; Ingrid Nygaard; Thomas M Braun; Matthew D Barber; Shawn Menefee; Joseph Schaffer; Anne M Weber; John Wei
Journal:  J Urol       Date:  2008-05-21       Impact factor: 7.450

9.  Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial.

Authors:  Arun Sahai; Mohammad Shamim Khan; Prokar Dasgupta
Journal:  J Urol       Date:  2007-06       Impact factor: 7.450

10.  European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.

Authors:  André Reitz; Manfred Stöhrer; Guus Kramer; Giulio Del Popolo; Emmanuel Chartier-Kastler; Jürgen Pannek; Harald Burgdörfer; Konrad Göcking; Helmut Madersbacher; Stefan Schumacher; Rudolf Richter; Jan von Tobel; Brigitte Schurch
Journal:  Eur Urol       Date:  2004-04       Impact factor: 20.096
View more
  1 in total

1.  Moving beyond ineffective medication for OAB.

Authors:  Stephen S Steele
Journal:  Can Urol Assoc J       Date:  2011-06       Impact factor: 1.862
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.